QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

Curis (CRIS) Stock Forecast, Price & News

$0.82
-0.01 (-1.20%)
(As of 06/8/2023 ET)
Compare
Today's Range
$0.79
$0.84
50-Day Range
$0.55
$0.99
52-Week Range
$0.47
$1.77
Volume
199,750 shs
Average Volume
435,637 shs
Market Capitalization
$79.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Curis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
995.2% Upside
$9.00 Price Target
Short Interest
Healthy
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

728th out of 981 stocks

Biological Products, Except Diagnostic Industry

119th out of 163 stocks


CRIS stock logo

About Curis (NASDAQ:CRIS) Stock

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

CRIS Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Curis (CRIS) Gets a Buy from JonesTrading
Curis Provides First Quarter 2023 Business Update
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Curis, Inc. Common Stock (CRIS)
Curis's Return On Capital Employed Overview
Q4 2022 Curis Inc Earnings Call
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
Curis Provides Fourth Quarter 2022 Business Update
What Wall Street expects from Curis's earnings
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
Curis Provides Third Quarter 2022 Business Update
See More Headlines

CRIS Price History

CRIS Company Calendar

Last Earnings
5/04/2023
Today
6/08/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
60
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+990.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,670,000.00
Net Margins
-501.08%
Pretax Margin
-501.08%

Debt

Sales & Book Value

Annual Sales
$10.16 million
Book Value
$0.48 per share

Miscellaneous

Free Float
90,502,000
Market Cap
$79.71 million
Optionable
Optionable
Beta
2.94

Social Links


Key Executives

  • James E. DentzerJames E. Dentzer
    President, Chief Executive Officer & Director
  • Diantha Duvall
    CFO, Treasurer & Chief Accounting Officer
  • Mark W. Noel
    VP-Technology Management & Intellectual Property
  • Robert E. Martell
    Head-Research & Development
  • Reinhard von Roemeling
    Senior Vice President-Clinical Development













CRIS Stock - Frequently Asked Questions

Should I buy or sell Curis stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings
or view top-rated stocks.

What is Curis' stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year price objectives for Curis' stock. Their CRIS share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 990.9% from the stock's current price.
View analysts price targets for CRIS
or view top-rated stocks among Wall Street analysts.

How have CRIS shares performed in 2023?

Curis' stock was trading at $0.55 on January 1st, 2023. Since then, CRIS stock has increased by 50.0% and is now trading at $0.8250.
View the best growth stocks for 2023 here
.

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRIS earnings forecast
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $2.30 million during the quarter, compared to the consensus estimate of $2.49 million. Curis had a negative trailing twelve-month return on equity of 103.76% and a negative net margin of 501.08%. During the same period in the prior year, the business earned ($0.18) earnings per share.

When did Curis' stock split?

Curis shares reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (5.73%), Citigroup Inc. (1.90%), Renaissance Technologies LLC (1.68%), BlackRock Inc. (1.44%), Two Sigma Advisers LP (0.64%) and CM Management LLC (0.57%).
View institutional ownership trends
.

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $0.83.

How much money does Curis make?

Curis (NASDAQ:CRIS) has a market capitalization of $79.71 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.

This page (NASDAQ:CRIS) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -